Phase 1/2 study of fractionated dose lutetium‐177–labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 ( 177 Lu‐J591) for metastatic castration‐resistant prostate cancer-Reference-Cited by-同舟云学术

Phase 1/2 study of fractionated dose lutetium‐177–labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 ( 177 Lu‐J591) for metastatic castration‐resistant prostate cancer

Published:2019-04-23 Issue:15 Volume:125 Page:2561-2569
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Tagawa Scott T.¹²³^ORCID,Vallabhajosula Shankar⁴,Christos Paul J.⁵³,Jhanwar Yuliya S.⁴,Batra Jaspreet S.²,Lam Linda¹,Osborne Joseph⁴,Beltran Himisha¹³⁶,Molina Ana M.¹³,Goldsmith Stanley J.⁴,Bander Neil H.²³,Nanus David M.¹²³

Affiliation:

1. Division of Hematology and Medical Oncology, Department of Medicine Weill Cornell Medicine New York New York

2. Department of Urology Weill Cornell Medicine New York New York

3. Meyer Cancer Center Weill Cornell Medicine New York New York

4. Division of Nuclear Medicine, Department of Radiology Weill Cornell Medicine New York New York

5. Department of Healthcare Policy and Research Weill Cornell Medicine New York New York

6. Dana Farber Cancer Institute Boston Massachusetts

Funder

U.S. Department of Defense

National Institutes of Health

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32072

Reference32 articles.

1. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer

2. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer

3. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

4. Prostate‐specific membrane antigen expression in normal and malignant human tissues;Silver DA;Clin Cancer Res,1997

5. Constitutive and antibody‐induced internalization of prostate‐specific membrane antigen;Liu H;Cancer Res,1998

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From Oncogenesis to Theranostics: The Transformative Role of PSMA in Prostate Cancer;Cancers;2024-08-31

2. Single Chelator–Minibody Theranostic Agents for⁸⁹Zr PET Imaging and¹⁷⁷Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer;Journal of Nuclear Medicine;2024-08-14

3. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer;Nature Reviews Urology;2024-07-08

4. Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going;Cancer Treatment Reviews;2024-06

5. 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice;Current Oncology;2024-03-07